๐ Join us tomorrow morning, Wednesday July 10th, for our second quarter 2024 earnings call. Conference call dial-in and replay information can be found ๐ฝ ๐ฝ ๐ฝ #Q22024 #earnings
Theratechnologies Inc.โs Post
More Relevant Posts
-
Tomorrow, we will announce our financial results for the 2nd quarter of 2023. All details in a nutshell: โก๏ธ 7 a.m. (CEST): Publication of our Q2 results โก๏ธ 9:30 a.m. (CEST): Media conference call โก๏ธ 2 p.m. (CEST): Conference call for analysts You can find further information here: https://lnkd.in/ew59HKhi #EMDresults #Q2 #FinancialResults
Half-Yearly Financial Report Q2/2023 | Merck KGaA, Darmstadt, Germany
emdgroup.com
To view or add a comment, sign in
-
We're thrilled to share the ๐ณ๐ฎ๐ป๐๐ฎ๐๐๐ถ๐ฐ ๐ผ๐๐๐ฐ๐ผ๐บ๐ฒ๐ of our ๐ฎ๐ฌ๐ฎ๐ฏ ๐ณ๐ถ๐ป๐ฎ๐ป๐ฐ๐ถ๐ฎ๐น ๐๐ฒ๐ฎ๐ฟ with you all! It's been a year of ๐ฟ๐ฒ๐บ๐ฎ๐ฟ๐ธ๐ฎ๐ฏ๐น๐ฒ ๐ฎ๐ฐ๐ต๐ถ๐ฒ๐๐ฒ๐บ๐ฒ๐ป๐๐ and ๐๐๐ฟ๐ฎ๐๐ฒ๐ด๐ถ๐ฐ ๐ฑ๐ฒ๐ฐ๐ถ๐๐ถ๐ผ๐ป๐ that set the stage for our continued ๐ด๐ฟ๐ผ๐๐๐ต ๐ฎ๐ป๐ฑ ๐๐๐ฐ๐ฐ๐ฒ๐๐ ๐ ๐ ๐ฅ๐ฒ๐ฐ๐ผ๐ฟ๐ฑ-๐๐ฟ๐ฒ๐ฎ๐ธ๐ถ๐ป๐ด ๐ฃ๐ฒ๐ฟ๐ณ๐ผ๐ฟ๐บ๐ฎ๐ป๐ฐ๐ฒ: In 2023, the Eckert & Ziegler Group saw a remarkable ๐ญ๐ญ% ๐ถ๐ป๐ฐ๐ฟ๐ฒ๐ฎ๐๐ฒ ๐ถ๐ป ๐๐ฎ๐น๐ฒ๐, soaring to an all-time high of โฌ๐ฎ๐ฐ๐ฒ.๐ญ ๐บ๐ถ๐น๐น๐ถ๐ผ๐ป. Our ๐ป๐ฒ๐ ๐ฝ๐ฟ๐ผ๐ณ๐ถ๐ for the year reached โฌ๐ฎ๐ฒ.๐ฏ ๐บ๐ถ๐น๐น๐ถ๐ผ๐ป, translating to earnings per share of โฌ1.26. These numbers underscore our dedication to delivering ๐๐ฎ๐น๐๐ฒ ๐ฎ๐ป๐ฑ ๐ถ๐ป๐ป๐ผ๐๐ฎ๐๐ถ๐ผ๐ป to our stakeholders. ๐ ๐ฆ๐๐ฟ๐ฎ๐๐ฒ๐ด๐ถ๐ฐ ๐ ๐ผ๐๐ฒ๐ ๐ณ๐ผ๐ฟ ๐๐ฟ๐ผ๐๐๐ต: Looking ahead, we're not resting on our laurels. The Executive and Supervisory Boards are proposing a ๐ฟ๐ฒ๐ฑ๐๐ฐ๐ฒ๐ฑ ๐ฑ๐ถ๐๐ถ๐ฑ๐ฒ๐ป๐ฑ ๐ผ๐ณ โฌ๐ฌ.๐ฌ๐ฑ ๐ฝ๐ฒ๐ฟ ๐๐ต๐ฎ๐ฟ๐ฒ to the Annual General Meeting. This decision is driven by our commitment to ๐ณ๐ถ๐ป๐ฎ๐ป๐ฐ๐ฒ ๐ต๐ถ๐ด๐ต-๐ฟ๐ฒ๐๐๐ฟ๐ป ๐ฝ๐ฟ๐ผ๐ท๐ฒ๐ฐ๐๐ in the rapidly growing market of radiopharmaceuticals, including the ๐ฒ๐ ๐ฝ๐ฎ๐ป๐๐ถ๐ผ๐ป of our ๐ด๐น๐ผ๐ฏ๐ฎ๐น ๐ฝ๐ฟ๐ผ๐ฑ๐๐ฐ๐๐ถ๐ผ๐ป capacities. Moreover, this dividend reduction aims to enhance our ๐ถ๐ป๐ฑ๐ฒ๐ฝ๐ฒ๐ป๐ฑ๐ฒ๐ป๐ฐ๐ฒ from external financing, ensuring long-term ๐๐๐๐๐ฎ๐ถ๐ป๐ฎ๐ฏ๐ถ๐น๐ถ๐๐. ๐ ๐๐ ๐ฐ๐ถ๐๐ถ๐ป๐ด ๐ฆ๐ฝ๐ถ๐ป-๐ข๐ณ๐ณ ๐ข๐ฝ๐ฝ๐ผ๐ฟ๐๐๐ป๐ถ๐๐: As an added bonus, Eckert & Ziegler ๐๐ต๐ฎ๐ฟ๐ฒ๐ต๐ผ๐น๐ฑ๐ฒ๐ฟ๐ are to ๐ฟ๐ฒ๐ฐ๐ฒ๐ถ๐๐ฒ a ๐๐ต๐ฎ๐ฟ๐ฒ ๐ผ๐ณ ๐ฃ๐ฒ๐ป๐๐ถ๐ ๐ฎ๐ฝ๐ต๐ฎ๐ฟ๐บ ๐๐ for each E&Z share in their depot as part of our planned spin-off. This move reflects our dedication to unlocking ๐ฎ๐ฑ๐ฑ๐ถ๐๐ถ๐ผ๐ป๐ฎ๐น ๐๐ฎ๐น๐๐ฒ for our loyal investors. While we at Eckert & Ziegler are aiming to focus on our ๐ฐ๐ผ๐ฟ๐ฒ ๐ฏ๐๐๐ถ๐ป๐ฒ๐๐ of providing medical radioisotopes, we still strongly believe in the ๐ด๐ฟ๐ฒ๐ฎ๐ ๐ฝ๐ผ๐๐ฒ๐ป๐๐ถ๐ฎ๐น ๐ผ๐ณ ๐ฃ๐ฒ๐ป๐๐ถ๐ ๐ฎ๐ฝ๐ต๐ฎ๐ฟ๐บ's pipeline and the vision of our colleagues. We're looking forward to presenting you with the ๐ผ๐ฝ๐ฝ๐ผ๐ฟ๐๐๐ป๐ถ๐๐ to be part of their exciting journey. ๐ ๐๐๐๐๐ฟ๐ฒ ๐ข๐๐๐น๐ผ๐ผ๐ธ: Looking ahead to the ๐ฎ๐ฌ๐ฎ๐ฐ ๐ณ๐ถ๐ป๐ฎ๐ป๐ฐ๐ถ๐ฎ๐น ๐๐ฒ๐ฎ๐ฟ, our Executive Board anticipates ๐๐ฎ๐น๐ฒ๐ nearing โฌ๐ฎ๐ฒ๐ฑ ๐บ๐ถ๐น๐น๐ถ๐ผ๐ป and expects ๐๐๐๐ง from continuing operations before one-off effects to reach approximately โฌ๐ฑ๐ฌ ๐บ๐ถ๐น๐น๐ถ๐ผ๐ป. These projections underscore our confidence in our strategic vision and our ability to capitalize on emerging opportunities in the market. ๐๏ธ ๐ฆ๐๐ฎ๐ ๐ง๐๐ป๐ฒ๐ฑ: Mark your calendars! The ๐ฑ๐ฒ๐๐ฎ๐ถ๐น๐ฒ๐ฑ annual ๐ณ๐ถ๐ป๐ฎ๐ป๐ฐ๐ถ๐ฎ๐น ๐๐๐ฎ๐๐ฒ๐บ๐ฒ๐ป๐๐ for 2023 will be published on ๐ ๐ฎ๐ฟ๐ฐ๐ต ๐ฎ๐ฎ, ๐ฎ๐ฌ๐ฎ๐ฐ. We invite you to dive deeper into our performance and join us as we continue our journey of growth and innovation. #nuclearmedicine #radiopharmaceuticals #fy2023 #annualreport ย
To view or add a comment, sign in
-
-
As you start to strategize and plan out potential thought-leadership opportunities for your organization, be sure to connect and collaborate with your teams and consider submitting a speaker proposal for AXS25. The deadline for submissions is 9/30 but we're rolling out the call for speakers throughout summer. #callforspeakers #thoughtleadership #speaker #conferencespeaker #asembia25 #specialtypharmacy #pharma #pharmacy #pharmaceuticals #lifesciences #patientengagement #patientaccess #healthpolicy #patientcare #patientvoice https://lnkd.in/ekayS3uN
AXS25 Summit (April 27 - May 1, 2025) - Las Vegas - Speaker Proposal Form
surveymonkey.com
To view or add a comment, sign in
-
Tomorrow, we will announce our financial results for the 3rd quarter of 2023. All details in a nutshell: โก๏ธ 7 a.m. (CET): Publication of our Q3 results โก๏ธ 9:30 a.m. (CET): Media conference call โก๏ธ 2 p.m. (CET): Conference call for analysts You can find further information here: https://lnkd.in/eRmPRD-g #EMDresults #Q3 #FinancialResults
Q3 2023 Results | Merck KGaA, Darmstadt, Germany
emdgroup.com
To view or add a comment, sign in
-
๐ฃ Read the latest case study in Cleanroom Technology featuring the custom iHP system integrated into Avid Bioservices' new facility!
Check out our article in Cleanroom Technology! This is a case study about iHP technology being implemented in Avid Bioservices, a large pharmaceutical manufacturer with a vast facility. Read how they had great success with iHP technology providing consistent, repeatable efficacy right here โก๏ธ https://loom.ly/lyMNNwE
flickread.com
To view or add a comment, sign in
-
Check out our article in Cleanroom Technology! This is a case study about iHP technology being implemented in Avid Bioservices, a large pharmaceutical manufacturer with a vast facility. Read how they had great success with iHP technology providing consistent, repeatable efficacy right here โก๏ธ https://loom.ly/lyMNNwE
flickread.com
To view or add a comment, sign in
-
#InvestorNews: #EYPT to report Q4 2023 financial results and recent corporate developments at our upcoming webcast. Learn more below:
EyePoint Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Resultsย on March 7, 2024 | EyePoint Pharmaceuticals
investors.eyepointpharma.com
To view or add a comment, sign in
-
Antibody drug conjugates (ADCs) are an important new modality that is showing great results in treating certain types of cancer.ย ย Manufacture of this drug class is complex insofar as it requires several GMP intermediates as inputs to the conjugation reaction to produce the drug substance.ย ย My team of technical consultants at Alira Health has a focus on biologics, and we do a lot of work with ADCs. I'm excited to announce publication of an article from my team entitled โManufacturing challenges of therapeutic antibody-drug conjugatesโย by Dr. Peter Alexander and colleagues. The article appears as a featured report in the September 2023 issue ofย BioProcess International. Read the full article here:ย https://lnkd.in/gs_TyPe4
September 2023 - Featured Report
secure.viewer.zmags.com
To view or add a comment, sign in
-
In-year ROI, advanced analytics, and renewed confidence to innovate - these are just a few milestoneโs UCB reached during our partnership. In a new case study, discover the strategies behind the company's success:
From Lagging to Leading: Building Capability to Meet Tomorrowโs Life Sciences Challenges
insights.northhighland.com
To view or add a comment, sign in
-
Are you struggling to effectively communicate the value of your products or services in todayโs competitive market? Join our September 28th webinar, where we dive into the critical role of value communication in determining your commercial success. https://lnkd.in/eMJGZ68a #valuecommunication
How value communication can make or break your commercial success?
certara.com
To view or add a comment, sign in